Zai Lab Business Summary

Zai Lab Ltd (ZLAB) operates as a commercial-stage biopharmaceutical company utilizing a "dual-engine" business model to generate revenue primarily through the commercialization of licensed and proprietary therapeutics in Greater China and the development of a global R&D pipeline. The company’s revenue is driven by product sales from its diverse portfolio, which includes high-growth assets like VYVGART for immunology and oncology treatments such as OPTUNE, QINLOCK, and AUGTYRO. Its primary business segments are categorized by therapeutic area: Oncology, Immunology, Neuroscience, and Infectious Diseases. Within the competitive landscape, Zai Lab contends with major biopharma players like BeiGene, Innovent Biologics, and HUTCHMED. The company distinguishes itself as a premier "partner-of-choice" for Western firms seeking China market entry while simultaneously transitioning into a global innovator with internally developed assets entering late-stage clinical trials. The company was founded by Dr. Samantha Du, a pioneer in the Chinese biotech sector who previously co-founded HUTCHMED and held leadership roles at Pfizer and Sequoia Capital China. The current executive leadership team includes Dr. Du as Chairperson and CEO, Josh Smiley (formerly CFO of Eli Lilly) as President and Chief Operating Officer, and Dr. Yajing Chen as Chief Financial Officer. Research and development efforts are spearheaded by Dr. Rafael G. Amado, President and Head of Global R&D. Zai Lab’s board of directors features prominent industry figures such as Lead Independent Director Dr. John Diekman (founder of 5AM Ventures) and Nisa Leung (Managing Partner at Qiming Venture Partners), reflecting a strong pedigree of institutional backing from investors like Vivo Capital and Qiming.